News

Diabetes patients in Bahrain have a new treatment option with the introduction of Sitagliptin, a drug designed specifically for individuals with Type 2 diabetes. This medication works by targeting incretin hormones (GLP1 and GIP) that stimulate the pancreas to produce more insulin and signal the liver to reduce glucose production. Dr. Wiam Hussein, an endocrinologist at the Joslin Diabetes Centre, explains that this novel drug offers a 24-hour glucose response and is available in various strengths. Sitagliptin can be used alone or in combination with other medications when previous treatments have failed to provide adequate glucose control. However, it is not recommended for Type 1 diabetes patients, children, pregnant women, or nursing mothers without caution. The drug's introduction is part of ongoing efforts to address the rising number of diabetes cases in the Middle East, driven by factors like genetics, obesity, and lack of exercise.